

Public Title	Stopping TKI in patients with CML in complete molecular remission (MR4)
Scientific Title	Multicenter prospective trial estimating the persistence of molecular remission in chronic myeloid leukemia after stopping TKI
Short Title	EuroSKI
Id KN/ELN	LN_CMLSTU_2012_494
Trialgroup	CML-Studiengruppe
Type of Trial	NIS, multicentric, single-group, prospective, open-label
Phase	N/A
Disease	Chronic myeloid leukemia(CML) Chronic Phase
Stage of Disease	Complete molecular remission (MR4)
Molecular Marker	BCR-ABL
Aim	<ul style="list-style-type: none">- Evaluation of molecular relapse-free survival after stopping TKI [survival without molecular relapse defined by BCR-ABL1 > 0.1% on the IS at one time point (loss of major molecular response, MMR)]- Clinical and biological profile of complete and major molecular remission persistence- Overall and progression-free survival and the probabilities of a restart of TKI without prior molecular relapse- Patient reported QoL and symptom burden over time- Saved treatment costs / country from the time off TKI therapy considering also the more frequent PCR monitoring- Registering patients in confirmed MR4 and MR4.5- Analysing the time to recovery of MR4 after loss of MMR
Inclusion Criteria	<ul style="list-style-type: none">- CML in CP under treatment with TKI in first line or in second line because of toxicity to first line TKI or with TKI in combination- Duration of TKI treatment before enrolment at least 3 years- At least complete molecular remission MR4 (either (i) detectable disease $\leq 0.01\%$ BCR-ABL IS or (ii) undetectable disease in cDNA with $\geq 10,000$ ABL or $\geq 24,000$ GUS transcripts) for at least one year; at least three PCR-results with MR4 within the last year (+- 2 months) before study entry and no PCR-results > 0.01% during the same period- Before inclusion confirmation of MR4 through a EUTOS-CMR laboratory- Baseline data and documentation on treatment before study entry available- Both sexes but fertile women only if using effective contraceptive- Health insurance coverage- 18 years or older- Known baseline data at diagnosis, EURO-Score
Exclusion Criteria	<ul style="list-style-type: none">- Hospitalized patients without ability to give informed consent- Adults under law protection or without ability to consent- Previous or planned allogeneic stem cell transplantation
Age	≥ 18 years
Status	Closed
start of Recruitment	31.05.2012
Recruiting countries	Germany France U.K. Czech Republic

Spain
Italy
Greece
Portugal
The Netherlands
Poland
Switzerland
Austria
Norway
Ireland
Finland
Denmark
Russian Federation
Sweden

Target Sample Size

500

Leader

Saußele, Prof. Dr. med., Susanne
Universitätsmedizin Mannheim
III. Medizinische Klinik
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
Tel: +49 (0)621 383-6966
Fax: +49 (0)621 383-73 1500
Email: studien.haematologie@medma.uni-heidelberg.de

Scientific Contact (WHO)

Saußele, Prof. Dr. med., Susanne
Universitätsmedizin Mannheim
III. Medizinische Klinik
Theodor-Kutzer-Ufer 1-3
68167 Mannheim
Tel: +49 (0)621 383-6966
Fax: +49 (0)621 383-73 1500
Email: studien.haematologie@medma.uni-heidelberg.de

Contact Person

principal investigator
Mahon, Prof. Dr., François-Xavier
Email: francoisxavier.mahon@umr5540.u-bordeaux2.fr

Biometrics
Guilhot, Dr. med., Francois
Tel: +33 (0)549 444201
Email: f.guilhot@chu-poitiers.fr

Biometrics
Pfirrmann, Dr., Markus
Tel: +49 (0)89 544201-40
Fax: +49 (0)89 544201-44
Email: pfi@ibe.uni-muenchen.de
Homepage: <http://www.ibe.med.uni-muenchen.de/>

Quality of life
Efficace, PhD, Fabio
Email: f.efficace@gimema.it

Administrative needs

Leopold, Susanne

Tel: +49 (0)621 383 6970

Fax: +49 (0)621 383 6969

Email: susanne.leopold@medma.uni-heidelberg.de

Study assistance

Bartsch, Gabriele

Tel: +49 (0)621 383 6967

Fax: +49 (0)621 383 2167/6969

Email: studien.haematologie@medma.uni-heidelberg.de

Supporters

European LeukemiaNet

Homepage: <http://www.leukemia-net.org>

Other Registers

ClinicalTrials.gov NCT01596114

European Clinical Trials Database - EUDRACT2011-000440-22